2025 AHA／AC C科学声明：在心血管疾病 一级预防中使用风险评估指导血压管理决策.pdfVIP

Circulation

AHA/ACCSCIENTIFICSTATEMENT

UseofRiskAssessmenttoGuideDecision-

MakingforBloodPressureManagementinthe

PrimaryPreventionofCardiovascularDisease:A

ScientificStatementFromtheAmericanHeart

AssociationandAmericanCollegeofCardiology

SadiyaS.Khan,MD,MSc,FAHA,FACC,Chair;MarwahAbdalla,MD,MPH,FAHA,FACC;NatalieA.Bello,MD,MPH,FACC;

CiantelA.Blyler,PharmD;JocelynCarter,MD,MPH;YvonneCommodore-Mensah,PhD,MHS,RN,FAHA,FACC;

KeithC.Ferdinand,MD,FAHA,FACC;HeatherM.Johnson,MD,MS,MMM,FAHA,FACC;DanielJones,MD,FAHA;

AmitKhera,MD,FAHA,FACC;PaulMuntner,PhD,FAHA;StaceySchott,MD,MPH;DaichiShimbo,MD;

SidneyC.Smith,Jr,MD,FAHA,MACC;SandraJ.Taler,MD,FAHA;EugeneYang,MD,MS,FACC;

DonaldM.Lloyd-Jones,MD,ScM,FAHA,FACC,ViceChair;onbehalfoftheAmericanHeartAssociationandAmerican

CollegeofCardiology

ABSTRACT:Riskassessmentplaysacentralroleintheprimarypreventionofcardiovasculardisease.The2017HighBlood

PressureClinicalPracticeGuidelineincorporatedquantitativeriskassessmentforthefirsttimetoguidetheinitiationof

Dantihypertensivedrugtherapyandrecommendedcalculationof10-yearriskofatheroscleroticcardiovasculardiseasewith

o

wthePooledCohortEquations.Althoughthe2025HighBloodPressureGuidelinereaffirmedthisoverarchingparadigm

n

l

oforrisk-basedinitiationofantihypertensivedrugtherapy,itupdatedtherecommendedriskmodeltothePredictingRisk

a

d

eofCardiovascularDiseaseEventsequations,whichestimate10-yearriskoftotalcardiovasculardisease(including

d

f

ratheroscleroticcardiovasculardiseaseandheartfailure),anddefinedanew